Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astonea LabsBOM:544409 12 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates BOM:544409 with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 964 Drug Manufacturers companies, Astonea Labs ranks worse than 85.68% on this metric.
The historical rank and industry rank for Astonea Labs's OCF Margin % or its related term are showing as below:
BOM:544409'
s OCF Margin % Range Over the Past 10 Years
Min: -16.85 Med: -1.59 Max: 9.9
Current: -16.79
During the past 5 years, the highest OCF Margin % of Astonea Labs was 9.90%. The lowest was -16.85%. And the median was -1.59%.
BOM:544409's OCF Margin % is ranked worse than 85.68% of 964
companies
in the Drug Manufacturers industry
Industry Median: 10.06
vs BOM:544409: -16.79
Astonea Labs OCF Margin % Related Terms
Astonea Labs OCF Margin % Historical Data
* Premium members only.
The historical data trend for Astonea Labs's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Astonea Labs's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astonea Labs OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astonea Labs's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Astonea Labs's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astonea Labs (BOM:544409) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Astonea Labs and its competitors. According to the industry distribution chart, Astonea Labs ranks #826 out of 964 companies in the Drug Manufacturers industry, placing it in the top 85.7%.
Is Astonea Labs' OCF Margin % too high?
Astonea Labs' current OCF Margin % is 0.00%. Based on the distribution chart, Astonea Labs ranks #826 out of 964 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Astonea Labs has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Astonea Labs' OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Astonea Labs ranks #826 out of 964 companies for OCF Margin %. This places Astonea Labs in the lower half of its industry. The industry median OCF Margin % is 10.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.06, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Astonea Labs and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astonea Labs's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astonea Labs stock overvalued right now?
Astonea Labs (BOM:544409) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Astonea Labs' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Astonea Labs (BOM:544409), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Astonea Labs Ltd is an India-based pharmaceutical and cosmetics company engaged in the manufacturing and development of healthcare and personal care products. The Company operates in the pharmaceuticals and cosmetics & personal care space, offering products that include generic medicines, OTC products, specialty therapeutics, nutraceuticals, and biosimilars, as well as skincare, haircare, anti-aging, ethical, and organic cosmetic products, supported by in-house research and development and contract manufacturing services. Its business activities are organized across key segments comprising Pharmaceuticals, Cosmetics & Personal Care, R&D & Innovation, and Contract Manufacturing (CDMO).
12GF Score
Get the complete analysis for BOM:544409
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544409 has been successfully added to your 
